http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Zai Lab (ZLAB) Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
-
Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
-
Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
-
Novocure (NVCR) Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC
-
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
-
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update
-
Novocure (NVCR) Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in NSCLC
-
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
-
Zai Lab (ZLAB) Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer, DMC Says Trial Should Continue
-
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
-
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
-
Novocure (NVCR) Reports Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC
-
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
-
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
-
Novocure to Report First Quarter 2021 Financial Results
-
Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
-
Novocure (NVCR) Adds Timothy J. Scannell to Board
-
Novocure Announces Addition to Its Board of Directors
-
Novocure (NVCR) Reports Prelim. Q4 Revenues
-
Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update
-
Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference
-
Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
-
Novocure (NVCR) Reports First Patient Enrolled in Global Phase 3 TRIDENT Trial of Optune
-
First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
-
Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference
-
Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting
-
Novocure (NVCR) Receives CE Mark for NovoTTF-100L System
-
Novocure Receives CE Mark for NovoTTF-100L™ System
-
Novocure Announces Agenda for Virtual Research and Development Day
-
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks
-
Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update
-
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research
-
Novocure to Report Third Quarter 2020 Financial Results
-
Novocure to Host Virtual Research & Development Day
-
Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community
-
Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
-
Novocure Announces Expansion of Its Executive Leadership Team
-
Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update
-
Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
-
Novocure (NVCR) Reports First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
-
First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
-
Novocure (NVCR) Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA in NSCLC
-
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
-
Novocure (NVCR) Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua
-
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
-
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
-
Novocure to Report Second Quarter 2020 Financial Results
-
Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data
-
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
-
Zai Lab (ZLAB), Novocure (NVCR) Announce China NMPA Approves Optune for Treatment of Newly Diagnosed and Recurrent Glioblastoma
